Benchmark analyst Bill Sutherland attributes recent weakness in shares of BioTelemetry (BEAT) to a short thesis on competitor iRhythm (IRTC) that was released in late March that makes "a strong case" for the potential of a sharp drop in reimbursement for the technical service on extended wear holters after 2021. BioTelemetry, unlike iRhythm, has just introduced its extended wear holter and that product only makes up about 1% of BioTelemetry's total revenue by his estimates, Sutherland tells investors. The analyst, who doesn't see a reimbursement change materially impacting BioTelemetry's long-term revenue growth, keeps a Buy rating and $82 price target on the shares, calling the selloff a buying opportunity.